Title
Category
Credits
Event date
Cost
Individualizing Treatment Selection for Pediatric and Adult Patients With Bipolar Depression
  • Bipolar Disorder
  • Depression
  • Antidepressants
  • Antipsychotics
  • Child and Adolescent Psychiatry
  • Diagnostic Tools
  • Mood Disorders
  • Patient/Physician Communication
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Drs Findling and Goldberg offer expertise on the diagnosis and treatment of bipolar disorder in patients of all ages.
Remission and Treatment Augmentation of Depression in the United States
  • Depression
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Closer monitoring of symptoms through measurement-based care and setting symptom remission as a goal can help improve outcomes for adults with depression.
Expanded Treatment Options and Addressing Unmet Needs in the Diagnosis and Treatment of Bipolar Disorder
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Bipolar disorder presents on a spectrum, with bipolar depression on one end and bipolar I on the other and a host of other presentations in between. As guidelines are updated and new treatments become available, developing individualized treatment regimens is key and collaboration between clinician and patient and family is critical in optimizing patient outcomes. Clinicians should use measurement-based care to assess whether treatment changes are necessary, which requires engaging with the patient to monitor efficacy and manage side effects.
Episode 1: Why the Duration Until Onset of Antidepressant Matters
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Pharmacology for MDD is limited by low efficacy, delayed response, and side effects. Research on the pathophysiology of the disease that includes the glutamatergic system and GABA signaling is ushering in a new era for rapidly acting antidepressants.
Episode 2: Update on Rapid-Onset Therapies for Major Depressive Disorder
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
The new fast-acting antidepressants esketamine, an NMDA receptor antagonist, and positive allosteric modulators of GABAergic neurotransmission brexanolone and zuranolone have created an important and exciting paradigm shift in the treatment of depression.
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
$0.00
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
Staying Up to Date with Evolving Postpartum Depression Pathophysiology and Treatment Research
  • Depression
  • Mood Disorders
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Early diagnosis of PPD is critical for mother-infant outcomes, and new hypotheses in its pathophysiology has led to novel and emerging therapies that can improve these outcomes.